September 23, 2017 6:08 PM ET


Company Overview of BioMotiv, LLC

Company Overview

BioMotiv, LLC, a development company, engages in licensing technologies across various disease areas and types of therapeutics—small molecules, antibodies, proteins, cell therapies, and nucleotides. BioMotiv, LLC has strategic partnerships with Arix Bioscience, River Laboratories, and River Laboratories. The company was formerly known as BIOU, LLC. BioMotiv, LLC was incorporated in 2010 and is based in Cleveland, Ohio.

20600 Chagrin Boulevard

Suite 210

Cleveland, OH 44122

United States

Founded in 2010





Key Executives for BioMotiv, LLC

Chief Executive Officer and Member of Board of Managers
Age: 45
Chief Business Officer
Age: 59
Senior Vice President and General Counsel
Vice President of Technical Operations
Legal Director
Compensation as of Fiscal Year 2017.

BioMotiv, LLC Key Developments

BioMotiv, LLC Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

BioMotiv, LLC Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

BioMotiv, LLC and Biogen Expand Strategic Partnership into Ophthalmology

BioMotiv, LLC announced that it has expanded its strategic partnership with Biogen to include the ophthalmology therapeutic area, in addition to its existing neurology partnership. This discovery collaboration will leverage the strengths of both organizations to identify pioneering ophthalmic discoveries and advance them into medicines. With the additional investment by Biogen of $10 million and commitments by other investors, the total capitalization for BioMotiv has now reached $145 million.

Charles River Laboratories International, Inc. Enters into Strategic Partnership with BioMotiv, LLC

Charles River Laboratories International, Inc. announced that it has entered into a strategic partnership with BioMotiv, LLC. Through this partnership, Charles River will provide discovery and preclinical development services that will enable BioMotiv to advance discoveries sourced from academic research and non-governmental organizations into novel medicines. Charles River has committed to invest up to $10 million in BioMotiv. Through the agreement, Charles River will be the preferred drug discovery and preclinical development partner for BioMotiv’s portfolio of technologies and companies. As part of this new relationship, Professor Julie Frearson, Executive Director of Scientific Alliances for Charles River, will be joining BioMotiv’s Advisory Board.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Private Placement
December 12, 2016
Allinaire Therapeutics, LLC

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioMotiv, LLC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at